Recommendation regarding Glybenclamide

@1354. SHRI SANTOSH KUMAR SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Government have recommended Glybenclamide as non-essential;

(b) whether it is also a fact that based on their certification, this drug has been price decontrolled on the ground that this is not in the World Health Organisation Essential list;

(c) what are the names of other drugs which are not in WHO list but are still in Category-II of price control;

(d) what are the reasons for special treatment for Glybenclamide;

(e) whether it is a fact that Government representatives in the Kelkar Committee took advice about this drug before agreeing to the proposal for exemption from price control; and

(f) if so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) and (b) No, Sir.

(c) Necessary information will be compiled and laid on the Table of the House.

(d) Glybenclamide has been excluded from price control on the recommendations contained in the Supplementary of the Kelkar Committee.

(e) and (f) No, Sir.

@Previously Unstarred Question 822 transferred from the 25th July, 1989.

ORS under National Health Programme

@@1355. SHRI P. N. SUKUL: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that ORS is required for National Health Programme;

(b) whether it is also a fact that Government have not recommended price decontrol of the same;

(c) if so, how this drug has been price decontrol;

(d) whether it is a fact that decontrol on its price has been recommended by a Committee *inter alia* having two experts from the Ministry of Health and Family Welfare; and

(e) what steps are being taken to review the matter, in view of the essentiality of this item for National Health Programme?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (e) ORS has been price decontrolled as per the recommendations contained in the Supplementary Report of the Kelkar Committee.

Contents of certain drugs

@@@1356. SHRI B. SATYANARAYAN REDDY: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 101 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) what are the products containing Calcium salts and Vitamins Iron + Folic Acid and Iron and Vitamins for which the prices have been reduced for the promulgation of DPCO, 1987.

(b) what were their prices before DPCO, 1987 and what are their revised prices, packwise, and what is the percentage of reduction; and

@@Previously Unstarred Question 837 transferred from the 25th July, 1989.

@@@Previously Unstarred Question 840 transferred from the 25th July, 1989.

(c) what is the position regarding overcharging of prices of Fefol and Fesofer and what has been done to punish the producer?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) (c) and (d) The Committee has referred to in part (a) of the question, fall under price control Category and prices of such formulations are revised as and when applications are received for price revision. However, the price of some Calcium and Iron formulations (single ingredient) falling under decontrolled category had been reduced due to Government's intervention as per details given below:

Sl. No.	Name of the Bulk Drugs/Formulation	Pack Size	Price fixed by the Co. after increasing it (Rs.)	Reduced price after Govt's intervention (Rs.)	% CHG.
1.	Calcium Syrup	200 ml	20.11	13.50	(—)32.9
2.	Calcium Injection	5×1 ml	23.63	12.75	(—)46.0
3.	Fersolate Tablets	500's	25.37	22.00	(—)13.3

(c) The required details to the extent available will be collected and laid on the table of the House.

Turnover of Psychotherapeutic drugs

@@@1357. SHRI P. N. SUKUL: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 111 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) whether it is a fact that the ten brands of Psychotherapeutic drugs accounted for a turnover of Rs. 15.40 crores according to ORG;

(b) whether it is also a fact that the actual sale of these drugs is of the order of Rs. 26 crores even in respect of these ten brands;

(c) whether it is also a fact that the total sale of psychotherapeutic drugs is over Rs. 70 crores per annum which makes them 4th leading group after Antibiotics, Vitamins and Analgesics; and

(d) how do they rank 4th in turnover as a group when the diseases for which they are used are not widely prevalent?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (d) Psychotherapeutic drugs have been excluded from price control based on the recommendations contained in the Supplementary Report of the Kelkar Committee. Sales turnover is not monitored by this Ministry.

Prices of drugs

£1398. SHRI SANTOSH KUMAR SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to Starred Question 101 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) on what basis it has been concluded that as a matter of fact the prices

@@@Previously Unstarred Question 841 transferred from the 25th July, 1989.

£Previously Unstarred Question 842 transferred from the 25th July, 1989.